Navigation Links
Updated Results from Phase 2 Trial Demonstrate Prolonged Hematologic Relapse-Free Survival of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia
Date:6/14/2010

BETHESDA, Md., June 14 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced the presentation of updated results from a Phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL).  Results of the analysis demonstrate that a prolonged hematologic relapse free survival was observed in patients treated with blinatumomab. As of April 2010, six of nine evaluable, MRD responding, non-transplanted patients were in hematologic remission, ranging up to 23 months.  Historical experience suggests that the majority of patients with MRD following front-line chemotherapy who do not receive a transplant will relapse within one year.  Blinatumomab is the first of a new class of agents called BiTE® antibodies, designed to harness the body's T cells to kill cancer cells.

Dr. Max Topp, Department of Internal Medicine II, University of Wuerzburg presented the study findings on June 12, 2010 in an oral presentation (abstract # 0598) at the 15th Annual Congress of the European Hematology Association (EHA) in Barcelona, Spain.

"Adult acute lymphoblastic leukemia is a difficult to treat disease that has seen no meaningful improvement in decades," said Dr. Topp.  "These data clearly demonstrate that blinatumomab has the potential to fundamentally change the outcome for patients with ALL."

Phase 2 Study Design

This multi-center Phase 2 study evaluated the efficacy and safety of blinatumomab in ad
'/>"/>

SOURCE Micromet, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Presents Updated IMPACT Results Confirming PROVENGE Improves Overall Survival in Patients With Metastatic Castrate-Resistant Prostate Cancer
2. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
3. Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results
4. Newly Updated Pharmacy State Law Compendium Available
5. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
6. Roxane Laboratories, Inc. Updated Launch of Calcium Acetate Capsules, 667mg
7. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
8. IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
9. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
10. ORTHO EVRA(R) Prescribing Information Updated
11. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... MONTREAL , Nov. 21, 2014 /PRNewswire/ ... that the European Medicines Agency (EMA) has ... the company,s lead product candidate, for the ... is a rare, severely disabling genetic disease ... tissue swelling (flare-ups) and new abnormal bone ...
(Date:11/21/2014)... Nov. 20, 2014  RedRick Technologies, a provider ... reading room environment guidance, has helped the new ... reading room, which may also serve as a ... Medicine. "In line with the ... of Radiology,s Imaging 3.0 ™ initiative, the ...
(Date:11/21/2014)... GABLES, Fla. , Nov. 20, 2014   ... to become the first U.S. commercial producer of Molybdenum-99 ... a contract with INVAP to design its ... Fla. Mo-99 is the parent isotope of ... medicine procedures worldwide. In 2012, Congress passed legislation making ...
Breaking Medicine Technology:Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 2RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 3Coqui RadioPharmaceuticals Inks Deal With INVAP 2
... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Biosciences, will be presenting at Citi,s 2011 Global Health Care ... presentation takes place on Tuesday, March 1, 2011 at 2:00 ... will be webcast and may be accessed on the Company,s ...
... Ortho Biotech Inc. (Centocor) today received a decision from ... Washington, D.C. overturning a 2009 federal court jury verdict ... Laboratories liable for patent infringement. A panel ... Centocor anti-tumor necrosis factor (TNF) -alpha rheumatoid arthritis treatments ...
Cached Medicine Technology:Court of Appeals Overturns $1.8 Billion Patent Verdict for Centocor Ortho Biotech Inc. 2
(Date:11/23/2014)... 23, 2014 SWAccessControl.com's high quality access ... Recently, the company has announced its new collection of ... on these high quality power suppliers. All the new ... The special offer lasts until Dec. 20, 2014. , ... them have been supporting it for a long time. ...
(Date:11/23/2014)... 2014 The FDA is Watching: , ... On-Demand Webinar**, Dec. 11, 2014 ? Any Time at ... focus on promotional activities is no longer limited to ... looking at websites, Twitter, journal articles, TV appearances, Facebook ... Dec. 11, for On-Demand access to Timothy Ayers and ...
(Date:11/22/2014)... (PRWEB) November 23, 2014 Every year ... their communities. AlignLife experience rapid growth in the Greenville, ... very unique opportunity. AlignLife of Simpsonville will ... offices for their first annual Toy Drive. These six ... they would support with this year's toy drive. With ...
(Date:11/22/2014)... black prom dress will never go out of fashion. BellasDress.com, ... new items of black prom gowns . Now all ... up to 70% off. People throughout the world can enjoy ... made with the best materials, can make wearers feel comfortable. ... company provides these beautiful outfits in a huge range of ...
(Date:11/22/2014)... 22, 2014 “Due to my knee replacement ... from Gurnee, Ill. “While using the ice grip attachment, I ... thought there needed to be a safer way to prevent ... BLOCK. , The SPIKE BLOCK offers added safety and stability ... help to reduce injuries and damage associated with traditional spiked ...
Breaking Medicine News(10 mins):Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 3Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 4Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 5Health News:Greenville Area AlignLife Offices Join Together for a Local Toy Drive 2Health News:New Black Prom Dresses from BellasDress.com 2
... new drug targets for mucosal fungus found in most ... genetic approach to improve treatment of common infections caused by ... by researchers at Georgetown University Medical Center. , The ... Ssk1 gene could offer a new drug target against the ...
... who report receiving written and verbal instructions on the ... significantly less likely to suffer the serious gastrointestinal and ... the drug, according to new research from the University ... the October issue Journal of General Internal Medicine ...
... Breast Cancer Funding to be a National Priority, DALLAS, ... Day,the Susan G. Komen for the Cure(R) Advocacy Alliance today ... -- that features a,bipartisan collection of voters declaring "I ... us in some way, and Americans all across,the country have ...
... American National,Insurance Company (Nasdaq: ANAT ) announced a ... share) compared to net income of,$79,245,000 ($2.98 per diluted ... security investments as well as,catastrophe losses in the property ... in earnings., After tax operating earnings for the ...
... Care, Inc. (DCI),announced today that it has completed ... PANCRECARB(R) (pancrelipase), used in the treatment,of Exocrine Pancreatic ... ("FDA"). The FDA had previously granted the product ... schedule., "Digestive Care has provided vital products ...
... providing the industry,s most aggressive defense, The Doctors Company, the largest ... is rolling out litigation education retreats for member physicians who are ... ... Calif. (Vocus) October 27, 2008 -- As part of its commitment ...
Cached Medicine News:Health News:Genetic Approach Boosts Yeast Infection Treatment 2Health News:Better instructions reduce complications among patients using common blood thinner 2Health News:Better instructions reduce complications among patients using common blood thinner 3Health News:Susan G. Komen for the Cure(R) Advocacy Alliance Unveils New 'I Vote for the Cure'(R) Web Video 2Health News:Susan G. Komen for the Cure(R) Advocacy Alliance Unveils New 'I Vote for the Cure'(R) Web Video 3Health News:American National Announces Third Quarter 2008 Results 2Health News:American National Announces Third Quarter 2008 Results 3Health News:American National Announces Third Quarter 2008 Results 4Health News:Digestive Care, Inc. Announces the Complete Submission of the NDA for PANCRECARB(R) (pancrelipase) 2Health News:The Doctors Company Launches Litigation Education Retreats to Assist Physicians Involved in Medical Litigation 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: